MRTP claim authorisation and General Snus sales in the USA: evidence from a difference-in-differences model

Author:

Liber Alex CORCID,Seidenberg Andrew BORCID,Pesko Michael FORCID

Abstract

BackgroundThe 2009 Tobacco Control Act granted the US Food and Drug Administration (FDA) regulatory authority over tobacco products, including the ability to authorise modified-risk tobacco product (MRTP) claims. In October 2019, the FDA authorised the first-ever MRTP claim for General Snus, which allowed the product to be marketed as reduced risk (relative to cigarettes). MRTP authorisation may increase otherwise low rates of snus use in the USA (<0.5% for children and adults).MethodsUsing 2017–2021 Nielsen sales data from 19 US states, we conducted a difference-in-differences analysis to determine whether logged unit sales of General Snus were affected by the MRTP authorisation, compared with (1) sales of other snus brands and (2) sales of non-snus smokeless products; we also examined (3) if sales of non-General Snus brands were affected by General Snus’s MRTP authorisation, compared with sales of non-snus smokeless tobacco products.ResultsAlthough sales declined in absolute terms, sales of General Snus relative to other snus brands were unchanged after MRTP authorisation (−9.0%, 95% CI −19.6% to 1.60%, p=0.098). However, compared with non-snus smokeless brand sales, sales of General Snus (+14.7%, 95% CI 5.23% to 24.2%, p=0.002) rose after MRTP authorisation. Compared with non-snus smokeless products, sales of non-General Snus brands also rose after MRTP authorisation (+23.7%, 95% CI 9.5% to 38.0%, p=0.001).ConclusionsAlthough only General Snus received MRTP authorisation, this designation appears to have slowed declines for the entire snus category. This suggests consumers may make determinations regarding product risk to a product class rather than individual products.

Funder

US National Cancer Institute

Center for the Assessment of Tobacco Regulations

National Institutes of Health

US Food and Drug Administration

National Institute On Drug Abuse of the National Institutes of Health

Publisher

BMJ

Subject

Public Health, Environmental and Occupational Health,Health (social science)

Reference9 articles.

1. US Food and Drug Administration . FDA grants first-ever modified risk orders to eight Smokeless tobacco products. 2022. Available: https://www.fda.gov/news-events/press-announcements/fda-grants-first-ever-modified-risk-orders-eight-smokeless-tobacco-products

2. US Food and Drug Administration . R.J. Reynolds tobacco company modified risk tobacco product (MRTP) applications. 2022. Available: https://www.fda.gov/tobacco-products/advertising-and-promotion/rj-reynolds-tobacco-company-modified-risk-tobacco-product-mrtp-applications

3. Office on Smoking and Health, Centers for Disease Control and Prevention . National youth tobacco survey (NYTS). smoking and tobacco use. 2023. Available: http://www.cdc.gov/tobacco/data_statistics/surveys/nyts

4. United States Department Of Health And Human Services. National Institutes Of Health . National Institute on drug abuse, United States Department of health and human services. Food and Drug Administration. center for tobacco products. population assessment of tobacco and health (PATH) study [United States] public-use files: version 17. 2022. doi:10.3886/ICPSR36498.V17

5. Difference-in-Differences with multiple time periods

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3